A series of novel 2-phenylaminopyrimidine (PAP) derivatives structurally related to Imatinib were designed and synthesized. The abilities of these compounds to inhibit proliferation were tested in human chronicmyeloid leukemia K562 cells and HL60cells. Compound (10c) was the most effective cell growth inhibitor in inhibiting K562 cells and compound (10f) was the most effective cell growth inhibitor in inhibiting HL60 cells.
